Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

preventive medicine --- personalised medicine --- predictive medicine --- participatory medicine --- P4 medicine --- chronic diseases --- p4 medicine

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

precision medicine --- oncology --- clinical medicine --- personalised medicine --- individualised therapy --- Personalized medicine --- Cancer --- Oncology --- Oncology. --- Personalized medicine. --- Treatment --- Treatment. --- Individualized medicine --- Medical care --- Pharmacogenetics --- Tumors --- Cancers --- Carcinoma --- Malignancy (Cancer) --- Malignant tumors --- Therapy --- Precision medicine --- Precision medicine. --- Médecine de précision --- Cancérologie --- Traitement

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

“Personalised Nutrition” represents any initiative that attempts to provide tailor-made healthy eating advice based on the nutritional needs of each individual, as these are dictated by the individual’s behaviour, phenotype and/or genotype, and their interactions. This Special Issue of Nutrients is dedicated to the development, implementation and assessment of the effectiveness of evidence-based “Personalised Nutrition” strategies. In this regard, a selection of reviews and original research manuscripts will bring together the latest evidence on how lifestyle habits, physiology, nutraceuticals, gut microbiome and genetics can be integrated into nutritional solutions, specific to the needs of each individual, for maintaining health and preventing diseases.

n/a --- gene-based --- taste --- postprandial leptin --- children --- personalised --- obesity --- macronutrient composition --- gastrointestinal symptoms --- postprandial adiponectin --- formula diet --- avoidance diet --- weight loss --- weight --- omega-3 fatty acids --- microbiome --- genotype --- nutrition --- direct-to-consumer test --- intervention --- clinical nutrition --- postprandial total ghrelin --- dietary intervention --- microbiota --- low-carbohydrate diet --- insulin --- FADS polymorphism --- adults --- genetics --- diet --- healthcare professionals --- HbA1c --- PROX1 gene --- phenotype --- high-fat meal --- glucose --- personalised nutrition --- irritable bowel syndrome --- dietary recommendation --- postprandial metabolic fingerprinting --- type 2 diabetes mellitus risk --- high-carbohydrate meal --- health --- ultra-high performance liquid chromatography --- food allergy --- normo-carbohydrate meal --- nutrimetabolomics --- type 2 diabetes --- nutrigenetics --- gene–diet interaction --- personalized nutrition --- gene-diet interaction

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

food production --- food safety --- green processing --- personalised nutrition --- health promotion --- Food industry and trade --- Nutrition --- Food industry and trade. --- Nutrition. --- Alimentation --- Food --- Health --- Physiology --- Diet --- Dietetics --- Digestion --- Food habits --- Malnutrition --- Food preparation industry --- Food processing industry --- Food technology --- Food trade --- Agricultural processing industries --- Processed foods --- Health aspects --- Processing

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics.

Medicine --- 5-fluorouracil --- capecitabine --- fluoropyrimidine --- thymidylate synthase --- thymidylate synthase enhancer region --- upstream stimulatory factor 1 --- adverse drug reactions --- pharmacogenomics --- epistasis --- random forest --- statin --- cardiovascular disease --- colorectal cancer --- personalised medicine --- toxicity --- (es)citalopram --- drug-gene-interaction --- drug-drug-interaction --- drug-drug-gene-interaction --- the PharmLines initiative --- antipsychotic agents --- pharmacogenetics --- cytochrome P-450 enzyme system --- psychotic disorders --- precision medicine --- direct oral anticoagulants --- clinical implementation --- atorvastatin --- SLCO1B1 --- HLA --- cutaneous adverse drug reaction --- SCAR --- genetic polymorphism --- antiepileptics --- CYP450 enzymes --- platelet reactivity --- single-nucleotide variants --- acute coronary syndrome --- clopidogrel --- genotype --- allele --- polymorphism --- HLA B --- CYP2C9*3 --- cutaneous adverse drug reactions (CADRs) --- anti-epileptic drugs (AEDS) --- phenytoin (PHT) --- genetic risk factors --- South India --- India --- cardiology --- adverse events --- guidelines --- 5-fluorouracil --- capecitabine --- fluoropyrimidine --- thymidylate synthase --- thymidylate synthase enhancer region --- upstream stimulatory factor 1 --- adverse drug reactions --- pharmacogenomics --- epistasis --- random forest --- statin --- cardiovascular disease --- colorectal cancer --- personalised medicine --- toxicity --- (es)citalopram --- drug-gene-interaction --- drug-drug-interaction --- drug-drug-gene-interaction --- the PharmLines initiative --- antipsychotic agents --- pharmacogenetics --- cytochrome P-450 enzyme system --- psychotic disorders --- precision medicine --- direct oral anticoagulants --- clinical implementation --- atorvastatin --- SLCO1B1 --- HLA --- cutaneous adverse drug reaction --- SCAR --- genetic polymorphism --- antiepileptics --- CYP450 enzymes --- platelet reactivity --- single-nucleotide variants --- acute coronary syndrome --- clopidogrel --- genotype --- allele --- polymorphism --- HLA B --- CYP2C9*3 --- cutaneous adverse drug reactions (CADRs) --- anti-epileptic drugs (AEDS) --- phenytoin (PHT) --- genetic risk factors --- South India --- India --- cardiology --- adverse events --- guidelines